胃癌组织与血清miR-126的表达及临床意义

doi:10.3969/j.issn.1004-616x.2017.04.006

癌变·畸变·突变 ›› 2017, Vol. 29 ›› Issue (4): 272-276,283.doi: 10.3969/j.issn.1004-616x.2017.04.006

胃癌组织与血清miR-126的表达及临床意义

龚瑜¹, 杨其昌², 袁荣华², 周峰², 李国利¹

1. 扬州大学医学院, 江苏扬州 225001;
2. 南通市第一人民医院, 江苏南通 226001

收稿日期:2017-04-10 修回日期:2017-05-10 出版日期:2017-07-31 发布日期:2017-07-31
通讯作者: 杨其昌,E-mail:ntyangqc@163.com;李国利,E-mail:glli@yzu.edu.cn E-mail:ntyangqc@163.com;glli@yzu.edu.cn
作者简介:龚瑜,E-mail:1186501106@qq.com。
基金资助:
国家自然科学基金面上项目（81273214）

GONG Yu¹, YANG Qichang², YUAN Ronghua², ZHOU Feng², LI Guoli¹

1. Medical College of Yangzhou University, Yangzhou 225001;
2. The First People's Hospital of Nantong, Nantong 226001, Jiangsu, China

Received:2017-04-10 Revised:2017-05-10 Online:2017-07-31 Published:2017-07-31

摘要/Abstract

摘要：

目的：分析胃癌患者癌组织与血清miR-126的表达水平，探讨胃癌组织与血清miR-126在胃癌诊断中的价值。方法：收集42对胃癌组织及其对应的远癌对照组织（距离癌组织5 cm以上）为实验组，60例年龄相近的健康人群作对照组，标本系胃癌根治术后新鲜标本，采集患者术前、术后1周及健康对照组人群的外周血各5 mL，采用实时定量PCR法检测miR-126在癌组织和患者血清中的表达情况，另采集患者术前、术后1周的外周血各5 mL送检验科做癌胚抗原（CEA）检测。根据组织及血清中miR-126检测结果和CEA值作ROC曲线判断诊断效率。结果：胃癌组织miR-126的相对表达水平低于远癌对照组织（t=7.276，P < 0.05）；miR-126在癌组织中的表达与肿瘤大小、临床分期、组织分化程度有关；在胃癌患者血清中，术前血清miR-126的相对表达水平低于术后（t=6.316，P < 0.05）；术后血清中的相对表达水平低于健康对照者（t=4.338，P < 0.05）；miR-126在血清中的表达与肿瘤临床分期、组织分化程度有关；胃癌组织miR-126的诊断效率ROC曲线下面积（AUC）为0.823，血清AUC为0.776，CEA的诊断效率AUC为0.537。Pearson相关分析显示，胃癌患者癌组织与术前血清中miR-126的相对表达水平呈正相关（r=0.484，P < 0.01）。结论：胃癌组织和血清中miR-126表达下调；血清miR-126可以作为评估胃癌患者病情严重程度的标志之一；血清miR-126的表达对胃癌具有较好的诊断价值，优于血清CEA；胃癌组织和血清miR-126的表达水平呈正相关，有望成为诊断早期胃癌和监测胃癌复发的生物学标志物。

关键词: miR-126, 胃癌组织, 血清, 实时定量PCR, 肿瘤标志物

Abstract:

OBJECTIVE: To analyze expression of miR-126 in the tissues and serum of gastric cancer as diagnostic biomarkers. METHODS: Subjects for the study group were 42 cases of gastric cancer patients. The control group were 60 healthy individuals of similar age and gender. Fresh surgical specimens were collected after radical gastrectomy. Blood samples were collected from controls and from the patients before and at one week after the operation. miR-126 expression in tissues and serum were analyzed using quantitative real-time PCR and CEA test in the lab. RESULTS: For gastric cancer tissues,miR-126 expression,which was related to tumor size,clinical stage and differentiation degree,was significantly lower in the cancer tissues than in the distal cancerous contrast tissues,t=7.276,P < 0.05. miR-126 expression in the pre-operative serum,which was related to tumor clinical stage and differentiation degree,was significantly lower than that in the post-operative serum,t=6.316,P < 0.05;and the miR-126 expression in the post-operative serum was significantly lower than that in the healthy control group,t=4.338,P < 0.05. The AUC of the ROC Curve of diagnostic efficiency of miR-126 expression was 0.823 in gastric cancer tissues and 0.776 in serum. The AUC of CEA diagnostic efficiency was 0.537,P > 0.05. Pearson correlation analysis showed positive correlation coefficient of miR-126 expression in tissues and pre-operative serum of gastric cancer at 0.484. CONCLUSION: miR-126 expression was down-regulated in gastric cancer tissues and serum. miR-126 expressions in the serum can possibly be used as an indicator for the severity of gastric cancer. miR-126 expressions in serum had desirable diagnostic values of gastric cancer,better than the serum CEA test. miR-126 expression levels in tissues and serum were positively related,therefore it may become valuable biomarkers for diagnosing early stage of gastric cancer and monitoring of recurrence.

中图分类号:

R363

龚瑜, 杨其昌, 袁荣华, 周峰, 李国利. 胃癌组织与血清miR-126的表达及临床意义[J]. 癌变·畸变·突变, 2017, 29(4): 272-276,283.

GONG Yu, YANG Qichang, YUAN Ronghua, ZHOU Feng, LI Guoli. null[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 272-276,283.

参考文献

[1] 姜可伟. 规范全球第二大致死率疾病的诊断——《胃癌诊断标准》解读[J]. 中国卫生标准管理,2010,(4):26-28.
[2] ARCHIE V C,KAUH J,JONES D V,et al. Gastric cancer:Standards for the 21st century[J]. Crit Rev Oncol Hematol,2006,57(2):123-131.
[3] 徐惠明,周明霞,张群雄,等. 血清肿瘤标志物AFP、CEA和CA199联合检测在消化系统恶性肿瘤诊断中的临床价值[J]. 实用临床医药杂志,2011,15(13):24-25.
[4] MITCHELL P S,PARKIN R K,KROH E M,et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A,2008, 105(30):10513-10518.
[5] CHEN X,BA Y,MA L,et al. Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res,2008,18(10):997-1006.
[6] LIU S,QIN X,ZHAO B,et al. Differential expression of miRNAs in esophageal cancer tissue[J]. Oncol Lett, 2013, 5(5):1639-1642.
[7] CHEN H,MIAO R,FAN J,et al. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma[J]. Clin Exp Metastasis,2013, 30(5):651-658.
[8] FENG R,CHEN X,YU Y,et al. miR-126 functions as a tumour suppressor in human gastric cancer[J]. Cancer Lett, 2010, 298(1):50-63.
[9] LI N,TANG A,HUANG S,et al. MiR-126 suppresses colon cancer cell proliferation and invasion vi inhibiting RhoA/ROCK signaling pathway[J]. Mol Cell Biochem, 2013:107-119.
[10] 张涛,张云宇,邵齐,等. 肾癌患者血清中miR-126的异常表达及其临床意义[J]. 临床与病理杂志,2016,36(7):905-908.
[11] 陈淑萍,陈燕. 消化系统恶性肿瘤患者肿瘤标志物癌胚抗原及癌抗原19-9和癌抗原242联检的临床意义[J]. 中国中西医结合消化杂志,2011,19(1):37-38.
[12] 叶建峰,蔡小红,吴永友,等. 多种肿瘤标志物在胃癌诊断中的价值[J]. 现代临床医学,2012,38(1):11-13.
[13] FENG R,CHEN X,YU Y,et al. miR-126 functions as a tumour suppressor in human gastric cancer[J]. Cancer Lett, 2010, 298(1):50-63.
[14] 龙丹,刘伏香,周艳,等. miR-126在宫颈癌组织中的表达及其临床意义[J]. 海南医学,2015,26(17):2513-2515.
[15] 李建芳,冯润华,陈雪华,等. miR-126在胃癌中的表达及其靶基因Crk的鉴定[J]. 外科理论与实践,2012,17(4):359-365.
[16] VRBA L,JENSEN T J,GARBE J C,et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells[J]. PLoS One,2010, 5(1).
[17] WEBER J,BAXTER D,ZHANG S,et al. The MicroRNA Spectrum in 12 Body Fluids[J]. Clin Chem,2010,56(11):1733-1741.
[18] 崔龙. 胃液微小RNA的分析及其在胃癌筛查中的意义[D]. 宁波:宁波大学,2012.
[19] VALADI H,EKSTROM K M,BOSSIOS A,et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells[J]. Nat Cell Biol,2007, 9(6):654-659.

胃癌组织与血清miR-126的表达及临床意义

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭玉凤, 孔晓娜, 张婷, 张超, 薛振伟, 李建军, 张晶, 周小林. 2015—2019年某焦化厂下风向居民血清免疫球蛋白分析[J]. 癌变·畸变·突变, 2022, 34(1): 14-19.
[2]	杨玉, 黄雅理, 林飞, 汤龙. 抗肿瘤血清胸腺因子9肽的急性毒性和遗传毒性[J]. 癌变·畸变·突变, 2022, 34(1): 57-61.
[3]	赵宁, 杜健鹏, 孙震晓. 鹿血清预处理对大鼠心肌细胞缺糖损伤的保护作用[J]. 癌变·畸变·突变, 2021, 33(1): 17-21.
[4]	杜强, 姚义勇, 曾刚. 基于TCGA数据库分析ASPM在肺腺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2020, 32(6): 457-463.
[5]	马鸣, 焦文静, 王延海, 颜晰, 张超, 张金艳. 弥漫大B细胞淋巴瘤患者血清IL-24及IL-6浓度检测的临床意义[J]. 癌变·畸变·突变, 2019, 31(3): 227-230.
[6]	崔宏伟, 苏秀兰. 胃癌干细胞在胃癌靶向治疗中的研究进展[J]. 癌变·畸变·突变, 2018, 30(6): 490-493.
[7]	蔡艺煌, 邓小玲, 黄文霞, 黄洁, 纪晴, 许铭炎. 慢病毒敲减质粒pLKO.1-hSRF的构建及鉴定[J]. 癌变·畸变·突变, 2018, 30(3): 234-238.
[8]	白玉勤, 吴宝, 张龙, 刘晓辉, 其木格, 刘帅莹, 韦学磊, 王徽. 非小细胞肺癌移植瘤侵袭组织中血清蛋白的分布[J]. 癌变·畸变·突变, 2018, 30(2): 132-135,139.
[9]	许镒洧, 郭竑, 郭海鹏, 彭裕辉. DKK1在食管胃结合部腺癌患者血清中的水平及其临床诊断价值[J]. 癌变·畸变·突变, 2017, 29(2): 139-142.
[10]	郭志兰, 车路阳, 李晶哲, 吴双, 孙震晓, 刘长振. Metridia荧光素酶检测条件的优化[J]. 癌变·畸变·突变, 2016, 28(6): 438-442.
[11]	程琳, 孙平楠, 谢庆东, 周小玲. 预扩增qPCR方法检测少量小鼠早期胚胎细胞中DNA甲基化相关基因的表达[J]. 癌变·畸变·突变, 2016, 28(1): 51-55.
[12]	由淑萍, 赵军, 木克热木·吐地买提, 马龙, 张石蕾, 刘涛. 肉苁蓉苯乙醇苷类成分对BSA诱导的肝纤维化大鼠转化生长因子β1表达的影响[J]. 癌变·畸变·突变, 2015, 27(6): 409-414.
[13]	李琳, 李孝鑫, 林仲武, 扈江伟, 张学清, 沈丽萍, 常诚, 陈英, 葛银林, 王治东. POLH mRNA作为辐射损伤分子生物标志物的可行性研究[J]. 癌变·畸变·突变, 2015, 27(6): 421-425,431.
[14]	蓝宇, 刘东东, 林明恩, 洪英楷, 黄建生, 陈思, 何学军. 沉默信息调节因子1在膀胱尿路上皮细胞癌中的表达与意义[J]. 癌变·畸变·突变, 2015, 27(2): 125-128.
[15]	周桂琴，张晓红，霍海燕，王媚媚，郭丽敏，温海英. 2，4-D丁酯对金鱼血清过氧化物酶和酯酶同工酶的影响[J]. 癌变·畸变·突变, 2014, 26(4): 261-265.